Felix Poppelaars1, Neeltina M Jager2, Juha Kotimaa3,4, Henri G D Leuvenink2, Mohamed R Daha1,3, Cees van Kooten3, Marc A Seelen1, Jeffrey Damman5. 1. Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 2. Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 3. Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands. 4. Hycult Biotech, Uden, the Netherlands. 5. Department of Pathology, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Kidneys derived from brain-dead (BD) donors have lower graft survival rates compared with kidneys from living donors. Complement activation plays an important role in brain death. The aim of our study was therefore to investigate the effect of C1-inhibitor (C1-INH) on BD-induced renal injury. METHODS: Brain death was induced in rats by inflating a subdurally placed balloon catheter. Thirty minutes after BD, rats were treated with saline, low-dose or high-dose C1-INH. Sham-operated rats served as controls. After 4 hours of brain death, renal function, injury, inflammation, and complement activation were assessed. RESULTS: High-dose C1-INH treatment of BD donors resulted in significantly lower renal gene expression and serum levels of IL-6. Treatment with C1-INH also improved renal function and reduced renal injury, reflected by the significantly lower kidney injury marker 1 gene expression and lower serum levels of lactate dehydrogenase and creatinine. Furthermore, C1-INH effectively reduced complement activation by brain death and significantly increased functional levels. However, C1-INH treatment did not prevent renal cellular influx. CONCLUSIONS: Targeting complement activation after the induction of brain death reduced renal inflammation and improved renal function before transplantation. Therefore, strategies targeting complement activation in human BD donors might clinically improve donor organ viability and renal allograft survival.
BACKGROUND: Kidneys derived from brain-dead (BD) donors have lower graft survival rates compared with kidneys from living donors. Complement activation plays an important role in brain death. The aim of our study was therefore to investigate the effect of C1-inhibitor (C1-INH) on BD-induced renal injury. METHODS:Brain death was induced in rats by inflating a subdurally placed balloon catheter. Thirty minutes after BD, rats were treated with saline, low-dose or high-dose C1-INH. Sham-operated rats served as controls. After 4 hours of brain death, renal function, injury, inflammation, and complement activation were assessed. RESULTS: High-dose C1-INH treatment of BD donors resulted in significantly lower renal gene expression and serum levels of IL-6. Treatment with C1-INH also improved renal function and reduced renal injury, reflected by the significantly lower kidney injury marker 1 gene expression and lower serum levels of lactate dehydrogenase and creatinine. Furthermore, C1-INH effectively reduced complement activation by brain death and significantly increased functional levels. However, C1-INH treatment did not prevent renal cellular influx. CONCLUSIONS: Targeting complement activation after the induction of brain death reduced renal inflammation and improved renal function before transplantation. Therefore, strategies targeting complement activation in human BD donors might clinically improve donor organ viability and renal allograft survival.
Authors: Juan S Danobeitia; Tiffany J Zens; Peter J Chlebeck; Laura J Zitur; Jose A Reyes; Michael J Eerhart; Jennifer Coonen; Saverio Capuano; Anthony M D'Alessandro; Jose R Torrealba; Daniel Burguete; Kevin Brunner; Edwin Van Amersfoort; Yolanda Ponstein; Cees Van Kooten; Ewa Jankowska-Gan; William Burlingham; Jeremy Sullivan; Arjang Djamali; Myron Pozniak; Yucel Yankol; Luis A Fernandez Journal: Am J Transplant Date: 2020-02-20 Impact factor: 8.086
Authors: Michael J Eerhart; Jose A Reyes; Casi L Blanton; Juan S Danobeitia; Peter J Chlebeck; Laura J Zitur; Megan Springer; Erzsebet Polyak; Jennifer Coonen; Saverio Capuano; Anthony M D'Alessandro; Jose Torrealba; Edwin van Amersfoort; Yolanda Ponstein; Cees van Kooten; William Burlingham; Jeremy Sullivan; Myron Pozniak; Weixiong Zhong; Yucel Yankol; Luis A Fernandez Journal: Transplantation Date: 2022-01-01 Impact factor: 5.385
Authors: Giuseppe Castellano; Rossana Franzin; Alessandra Stasi; Chiara Divella; Fabio Sallustio; Paola Pontrelli; Giuseppe Lucarelli; Michele Battaglia; Francesco Staffieri; Antonio Crovace; Giovanni Stallone; Marc Seelen; Mohamed R Daha; Giuseppe Grandaliano; Loreto Gesualdo Journal: Front Immunol Date: 2018-05-23 Impact factor: 7.561
Authors: Mariana Gaya da Costa; Felix Poppelaars; Cees van Kooten; Tom E Mollnes; Francesco Tedesco; Reinhard Würzner; Leendert A Trouw; Lennart Truedsson; Mohamed R Daha; Anja Roos; Marc A Seelen Journal: Front Immunol Date: 2018-11-20 Impact factor: 7.561
Authors: Judith E van Zanden; Neeltina M Jager; Mohamed R Daha; Michiel E Erasmus; Henri G D Leuvenink; Marc A Seelen Journal: Front Immunol Date: 2019-02-27 Impact factor: 7.561
Authors: Neeltina M Jager; Judith E van Zanden; Marta Subías; Henri G D Leuvenink; Mohamed R Daha; Santiago Rodríguez de Córdoba; Felix Poppelaars; Marc A Seelen Journal: Front Immunol Date: 2019-11-01 Impact factor: 7.561